Uncertainty and Medical Decision Making

Last registered on November 18, 2022
View Trial History

Pre-Trial

Trial Information

General Information

Title
Uncertainty and Medical Decision Making
RCT ID
AEARCTR-0010386
Initial registration date
November 14, 2022

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
November 18, 2022, 12:13 PM EST

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

Country
United States of America
Region

Primary Investigator

Name
Yudi Wang
Affiliation
Cornell University
Contact Primary Investigator

Other Primary Investigator(s)

Additional Trial Information

Status
In development
Start date
2022-11-21
End date
2023-01-31
Keywords
Behavior, Other
Additional Keywords
JEL code(s)
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
Abstract
The project seeks to quantify the uncertainty in peoples' belief of their health related risk, assess how information will change the uncertainty in people's such beliefs, and identify how the uncertainty in people's health related beliefs affect their decision to pursue medical test and preventative care. The study will be conducted in the context of breast cancer and mammograms for women over the age of 35.
External Link(s)

Registration Citation

Citation
Wang, Yudi. 2022. "Uncertainty and Medical Decision Making ." AEA RCT Registry. November 18. https://doi.org/10.1257/rct.10386-1.0
Sponsors & Partners
Experimental Details

Interventions

Intervention(s)
The main intervention consists of providing participants with their estimated breast cancer risk
Intervention Start Date
2022-11-21
Intervention End Date
2023-01-01

Primary Outcomes

Primary Outcomes (end points)
Uncertainty in belief of participants' breast cancer risk, participants' breast cancer risk, and participants' likelihood to get mammogram
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
We will randomly assign 45% of participants to the treatment group to receive information on their estimated breast cancer risk, 45% of participants to the control group, and the remaining 10% to the information evaluation group to assess how they value the information on their breast cancer risk
Experimental Design Details
Randomization Method
Randomization through Qualtrics
Randomization Unit
Individual
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
500 participants
Sample size: planned number of observations
500 participants
Sample size (or number of clusters) by treatment arms
225 participants treatment, 225 participants control, and 50 participants information evaluation.
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
Supporting Documents and Materials
IRB

Institutional Review Boards (IRBs)

IRB Name
Cornell Universitys IRB
IRB Approval Date
2022-11-04
IRB Approval Number
N/A
Analysis Plan

Post-Trial

Post Trial Information

Study Withdrawal

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Intervention

Is the intervention completed?
No
Data Collection Complete
Data Publication

Data Publication

Is public data available?
No

Program Files

Program Files
Reports, Papers & Other Materials

Relevant Paper(s)

Reports & Other Materials